I

Isomorphic Labs

AI-powered drug discovery and development

Research Leader - In-vitro Pharmacology, Exploratory Sciences

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeLondon, UKNo salary listed

About the Job

Requirements

  • A PhD or equivalent industrial/research experience in Pharmacology, Biochemistry, Biophysics, Cell Biology, or a related discipline, with significant years in biotech or pharmaceutical drug discovery.
  • Expert knowledge of in vitro pharmacology and biophysics, including designing robust screening cascades from Target Identification through Hit-to-Lead and Lead Optimisation.
  • Hands-on experience with one or more novel modalities, such as targeted protein degradation, molecular glues, peptides, or induced proximity.
  • Proven experience leading and developing scientists and managing contract research organisation studies.
  • Experience with, or clear enthusiasm for, large language model agentic workflows, in silico hypothesis building, and data-driven discovery.
  • Ability to work across multiple projects and therapeutic areas in an interdisciplinary environment.
  • Effective communication with stakeholders across a broad interdisciplinary team.
  • Experience validating virtual screens, de novo designs, or machine-learning-predicted binders.
  • Experience with laboratory automation and high-throughput data infrastructure.
  • Scripting or data analysis skills, such as Python or R, or experience building agents or prompts for scientific workflows.
  • Track record of authorship of relevant scientific manuscripts or patents.

Responsibilities

  • Set the in vitro pharmacology vision for exploratory programmes across targeted protein degradation, molecular glues, peptides, and next-generation modalities.
  • Assess the tractability of new modalities against challenging targets and set rigorous go/no-go criteria.
  • Turn therapeutic concepts and target product profiles into rigorous screening cascades for internal and partnered programmes.
  • Lead the design of biochemical, biophysical, and bespoke screening cascades for novel modalities, including surface plasmon resonance or grating-coupled interferometry, nano differential scanning fluorimetry, Spectral Shift, and microscale thermophoresis.
  • Develop quantitative assays covering binding kinetics, ternary complexes, degradation, and functional pathway readouts, including HiBiT, NanoBRET, and TR-FRET.
  • Work closely with medicinal chemistry and drug metabolism and pharmacokinetics teams to drive structure–activity relationship work and compound de-risking.
  • Set data quality, ontology, and quality-control standards so internal and contract research organisation data are machine-learning-ready from the start.
  • Champion the use and co-development of large language model agentic workflows to speed up hypothesis generation, experimental design, and data synthesis.
  • Work with machine learning and engineering teams on platform builds, contributing biological domain expertise to model and workflow design.
  • Test in silico hypotheses rigorously in the wet lab and build plans that advance programmes and fill systematic gaps in models.
  • Give stakeholders and collaborative teams critical biological input to guide generative design for new modalities.
  • Lead a team of Research and Senior Research Investigators, with an approximately equal split between scientific direction and people and contract research organisation leadership.
  • Design, manage, and lead the execution of contract research organisation and academic studies that deliver decision-quality data.

About the Company

Isomorphic Labs

AI-powered drug discovery and development

Isomorphic Labs uses artificial intelligence to speed up drug discovery and development. It applies machine learning and computational methods—building predictive and generative models—to accelerate how drugs are designed and how medical research is conducted. The company differentiates itself by combining the AI breakthroughs from Google DeepMind with Alphabet backing, enabling fast experimentation and scaling across biology while maintaining startup-style agility. Its goal is to bring safer, more effective therapies to market more quickly by advancing AI-driven medicine using deep learning, reinforcement learning, and other advanced techniques.

Company size
201-500
Company stage
Series C
Total funding
$7.7B
Headquarters
London, United Kingdom
Founded
2021

Recently Posted Jobs

Explore more opportunities at Isomorphic Labs

See more jobs